- Home
- FBRX vs BLUE Comparison
FBRX vs BLUE Comparison
Compare FBRX & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- BLUE
- Stock Information
- Founded
- FBRX N/A
- BLUE 1992
- Country
- FBRX United States
- BLUE United States
- Employees
- FBRX N/A
- BLUE N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBRX Health Care
- BLUE Health Care
- Exchange
- FBRX Nasdaq
- BLUE Nasdaq
- Market Cap
- FBRX 35.3M
- BLUE 36.9M
- IPO Year
- FBRX N/A
- BLUE 2013
- Fundamental
- Price
- FBRX $5.97
- BLUE $4.09
- Analyst Decision
- FBRX Strong Buy
- BLUE Hold
- Analyst Count
- FBRX 3
- BLUE 7
- Target Price
- FBRX $80.50
- BLUE $44.60
- AVG Volume (30 Days)
- FBRX 32.5K
- BLUE 524.5K
- Earning Date
- FBRX 05-12-2025
- BLUE 05-08-2025
- Dividend Yield
- FBRX N/A
- BLUE N/A
- EPS Growth
- FBRX N/A
- BLUE N/A
- EPS
- FBRX N/A
- BLUE N/A
- Revenue
- FBRX N/A
- BLUE $83,807,000.00
- Revenue This Year
- FBRX N/A
- BLUE $218.58
- Revenue Next Year
- FBRX N/A
- BLUE N/A
- P/E Ratio
- FBRX N/A
- BLUE N/A
- Revenue Growth
- FBRX N/A
- BLUE 184.12
- 52 Week Low
- FBRX $4.11
- BLUE $3.56
- 52 Week High
- FBRX $28.68
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- FBRX 42.87
- BLUE 43.15
- Support Level
- FBRX $5.25
- BLUE $3.83
- Resistance Level
- FBRX $7.67
- BLUE $5.15
- Average True Range (ATR)
- FBRX 0.92
- BLUE 0.40
- MACD
- FBRX 0.17
- BLUE -0.05
- Stochastic Oscillator
- FBRX 38.44
- BLUE 18.44
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.